Eddy Pharmaceuticals announced that the company's board of directors reviewed and approved a plan to issue A-shares to specific targets in 2026. The total amount of capital to be raised is no more than 945 million yuan for a global clinical development project for a novel HIV integrase inhibitor, an anti-AIDS solid drug project with an annual output of 500 million tablets, and supplementary working capital.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.